Bilastine clinical trials
How each study uses bilastine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
22 studies that test it; most in 2006 (3)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 3 |
| 2010 | 3 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 18 · Other 4
Faes Farma, S.A. (14) · Menarini International Operations Luxembourg SA (2) · Charite University, Berlin, Germany (2) · Universidade do Sul de Santa Catarina (1) · Yuhan Corporation (1) · Grupo de Alergología Clínica y Experimental (1) · A.Menarini Asia-Pacific Holdings Pte Ltd (1)
Often tested with
Tested in the same studies.
Montelukast (1) · Loratadine (1) · Cetirizine (1) · Desloratadine (1) · Fexofenadine (1) · Ebastine (1)
Related medicines
As reviewed, each with the page that says it.
- One of Antihistamines source
Studies
Open first, then newest update. How each study uses bilastine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 22
- A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® ModelCompletedPhase 2Faes Farma, S.A.NCT03231969Written as Bilastine 0.2%
- Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in ChildrenCompletedPhase 3Faes Farma, S.A.NCT04810390Written as Bilastine
- A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.CompletedPhase 3Faes Farma, S.A.NCT03479307Written as Bilastine Ophthalmic Solution 0.6%
- Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and AsthmaCompletedPhase 4Menarini International Operations Luxembourg SANCT02761252Written as Bilastine 20mg
- PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)CompletedPhase 2Faes Farma, S.A.NCT00574210Written as Bilastine
- Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SARCompletedPhase 2Faes Farma, S.A.NCT00574379Written as Bilastine
- Different Level of Single-dose and Multiple-dose Bilastine PK Study in Chinese PopulationStatus unknownPhase 1A.Menarini Asia-Pacific Holdings Pte LtdNCT03633760Written as Bilastine 40mg single dose
- Quality of Life in Patients With Allergic Rhinitis: Clinical Trial With Bilastine or LoratadineCompletedPhase 4Universidade do Sul de Santa CatarinaNCT02513290Written as Bilastine
- Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or UrticariaCompletedPhase 4Menarini International Operations Luxembourg SANCT02576041Written as Bilastine
- Bilastine Updosing in Chronic Spontaneous UrticariaCompletedPhase 3Charite University, Berlin, GermanyNCT02213367Written as Bilastine
- Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic RhinitisCompletedPhase 3Yuhan CorporationNCT01400828Written as Bilastine
- Evaluation of the Inhibitory Effect of 5 Anti-Histamines in UrticariaCompletedPhase 4Grupo de Alergología Clínica y ExperimentalNCT01940393Written as Bilastine
- Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)CompletedPhase 1/2Faes Farma, S.A.NCT01081574Written as Bilastine
- Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety ExtensionCompletedPhase 3Faes Farma, S.A.NCT01127620Written as Bilastine
- Oral Bioavailability of BilastineCompletedPhase 1Faes Farma, S.A.NCT01124123Written as Bilastine
- Human Mass Balance Study With BilastineCompletedPhase 1Faes Farma, S.A.NCT00572611Written as [14C]-bilastine
- Bilastine Updosing - Characterization of Underlying MechanismsCompletedPhase 2/3Charite University, Berlin, GermanyNCT01271075Written as Bilastine
- A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge ChamberCompletedPhase 2Faes Farma, S.A.NCT00420082Written as Bilastine
- Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic UrticariaCompletedPhase 3Faes Farma, S.A.NCT00421109Written as Bilastine
- Efficacy Study for the Symptomatic Treatment of Seasonal Allergic RhinitisCompletedPhase 3Faes Farma, S.A.NCT00504933Written as bilastine
See all 22 studies that test bilastine →
Given beside what is tested · 1 — bilastine is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with bilastine
Codes
What other systems call bilastine · ClinicalTrials.gg INT004413
- MeSH (NLM) C445659bilastineOne source NLM
- UNII (FDA) PA1123N395BILASTINEConfirmed FDA, NLM, Wikidata
- Wikidata Q2902977bilastineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C73045BilastineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C445659 | bilastine | One source NLM |
| UNII (FDA) | PA1123N395 | BILASTINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q2902977 | bilastine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C73045 | Bilastine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.